Search - Prime Therapeutics

388 Results for GLP-1 Pipeline Update

Reuters: Exclusive: Most patients using weight-loss drugs like Wegovy stop within a year, data show

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: Most patients stop using Wegovy, Ozempic for weight loss within two years

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
NBC News: Most people stop using Wegovy and Ozempic after 2 years, analysis finds

NBC News: Patients weren't asked why they quit taking the weight loss drugs

PA Sub-Categories: GLP-1 Prime Article: In the News
April Fraud Focus: The latest schemes and FWA trends

Jessica Johnson, clinical consultant at Prime Therapeutics, shares how the Special Investigations Unit (SIU) helps prevent fraud, waste and abuse (FWA) in health care

Prime Article: Perspectives